Mega Genomics Limited (HKG:6667)

Mega Genomics Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	45.05	30.04	-17.62	79.02
Depreciation & Amortization	14.51	14.97	15.12	13.77
Other Amortization	0.16	0.16	0.16	0.11
Loss (Gain) From Sale of Investments	-1.2	0.43	0.17	-0.06
Stock-Based Compensation	2.42	7.29	4.95	-
Provision & Write-off of Bad Debts	-7.92	-13.98	25.85	6.17
Other Operating Activities	-0.04	-1.62	-29.47	10.13
Change in Accounts Receivable	33.74	82.92	-7.05	-79.56
Change in Inventory	-0.2	-0.9	-0.22	-0.31
Change in Accounts Payable	-14.11	4.78	5.56	2.31
Change in Unearned Revenue	-3.65	42.41	-	-
Change in Other Net Operating Assets	-11.62	-2.81	-4.36	-0.94
Operating Cash Flow	57.15	163.68	-6.91	30.63
Operating Cash Flow Growth	-65.09%	-	-	-70.22%
Capital Expenditures	-0.76	-35.86	-5.01	-4.16
Sale (Purchase) of Intangibles	-0.01	-0.24	-0.18	-0.26
Investment in Securities	7.4	2.34	2.63	2.71
Investing Cash Flow	6.63	-33.75	-2.56	-1.71
Long-Term Debt Issued	-	23.56	-	-
Long-Term Debt Repaid	-12.52	-9.35	-7.32	-10.59
Net Debt Issued (Repaid)	-12.52	14.21	-7.32	-10.59
Issuance of Common Stock	-	-	184.16	228.82
Repurchase of Common Stock	-77.62	-26	-	-214.14
Other Financing Activities	-1.72	-1.12	-18.38	-1.47
Financing Cash Flow	-91.85	-12.91	158.46	2.62
Foreign Exchange Rate Adjustments	0.04	1.44	11.75	-0.89
Net Cash Flow	-28.03	118.46	160.74	30.65
Free Cash Flow	56.39	127.83	-11.92	26.47
Free Cash Flow Growth	-55.89%	-	-	-74.00%
Free Cash Flow Margin	34.34%	84.49%	-8.18%	11.16%
Free Cash Flow Per Share	0.27	0.60	-0.06	0.21
Cash Interest Paid	1.72	1.12	0.72	0.79
Cash Income Tax Paid	5.32	3.9	11.26	10.62
Levered Free Cash Flow	41.23	98.38	22.72	-193.51
Unlevered Free Cash Flow	42.31	99.08	23.17	-189.19
Change in Working Capital	4.17	126.4	-6.07	-78.5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.